ReviewHematology. American Society of Hematology. Education Program2024
Newborn screening initiatives for sickle cell disease in Africa.
Review in Hematology. American Society of Hematology. Education Program, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A qualitative evidence synthesis on perinatal screening for sickle cell disease in high-burden countries.BMC global and public health · 2026Pooled it
- Pooled it
- Ethical, Legal, and Social Implications of Newborn Screening in Africa: A Scoping Review.International journal of neonatal screening · 2026Review
- Birth Prevalence of Sickle Cell Disease in India: A Systematic Review and Meta-Analysis.International journal of neonatal screening · 2026Review
- Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.International journal of neonatal screening · 2026Review
- From policy to practice: World Health Organization's contribution to safer blood transfusions in Africa for sickle cell management - a review.Annals of medicine and surgery (2012) · 2026Review
- Integrated Newborn Screening in Nigeria: The Way Forward, A Workshop Report.International journal of neonatal screening · 2026Article
- Advances and Gaps in Global Newborn Screening for Sickle Cell Disease.International journal of neonatal screening · 2026Article
- Review
- Globalizing newborn screening: bridging gaps in genetic diagnosis and treatment.Frontiers in pediatrics · 2025Article
- Newborn screening for sickle cell disease in Caluquembe, southwestern Angola, 2024-2025.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sickle cell disease (SCD) is a genetic blood disorder in high prevalence in sub-Saharan Africa (SSA) that leads to high morbidity and early mortality. Newborn screening (NBS) with evidence-based interventions saves lives of individuals with SCD. SSA accounts for 75% of the global prevalence of SCD, but it has not been able to implement universal NBS for SCD. This article examines policy framework for NBS in SSA; the methods, processes, barriers, and enablers of NBS; and enrollment in comprehensive care to make available the evidence-based interventions that caregivers need to access in order to save the lives of babies with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.